Oral Pirfenidone for the Pulmonary Fibrosis of Hermansky-Pudlak Syndrome - Related Studies

Oral Pirfenidone for the Pulmonary Fibrosis of Hermansky-Pudlak Syndrome

This study is currently recruiting participants.

Study NCT00001596. Last updated on September 15, 2008. Information provided by National Institutes of Health Clinical Center (CC)

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Albinism
		Inborn Errors of Metabolism
		Oculocutaneous Albinism
		Platelet Storage Pool Deficiency
		Pulmonary Fibrosis

2	Additional conditions recognized in this trial
		Albinism, Oculocutaneous
		Fibrosis
		Hermanski-Pudlak Syndrome
		Metabolism, Inborn Errors
		Syndrome

3	More general conditions related to this trial
		Amino Acid Metabolism, Inborn Errors
		Blood Coagulation Disorders
		Blood Coagulation Disorders, Inherited
		Blood Platelet Disorders
		Disease
		Eye Diseases
		Eye Diseases, Hereditary
		Genetic Diseases, Inborn
		Hematologic Diseases
		Hemorrhagic Disorders
		Hypopigmentation
		Lung Diseases
		Lung Diseases, Interstitial
		Metabolic Diseases
		Pathologic Processes
		Pigmentation Disorders
		Respiratory Tract Diseases
		Skin Diseases
		Skin Diseases, Genetic

4	Interventions listed in this trial
		Pirfenidone (Deskar)
		Pirfenidone

5	More general drug interventions related to this trial
		Analgesics
		Analgesics, Non-Narcotic
		Anti-Inflammatory Agents
		Anti-Inflammatory Agents, Non-Steroidal
		Antineoplastic Agents
		Antirheumatic Agents
		Central Nervous System Agents
		Peripheral Nervous System Agents
		Pharmacologic Actions
		Physiological Effects of Drugs
		Sensory System Agents
		Therapeutic Uses

6	Sponsors listed in this trial
		National Human Genome Research Institute (NHGRI)